Application of bap18 in breast cancer resistance to endocrine therapy

A 1. BAP18, breast cancer technology, applied in the field of biomedicine, can solve the problem that other functions of BAP18 have not been reported, and achieve the effect of increasing clinical treatment effect, improving treatment effect, and promoting cancer process.

CN111973745BActive Publication Date: 2022-07-26中国医科大学
7 Cites 0 Cited by

Patent Information

Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Publication Date
2022-07-26

Smart Images

  • Figure 1
    Figure 1
  • Figure 2
    Figure 2
  • Figure 3
    Figure 3
Patent Text Reader

Abstract

The invention belongs to the technical field of biomedicine, and particularly relates to the application of BAP18 in breast cancer endocrine therapy resistance. Application of a targeting inhibitor of BAP18 in the preparation of a medicament for treating breast cancer, the targeting sequence of the inhibitor is SEQ ID No. 1. Experiments show that BAP18 can promote endocrine drug resistance in breast cancer and is involved in tumor resistance in a tamoxifen mouse model. BAP18 has potential function of drug resistance in breast cancer endocrine drugs, preparation of BAP18 small molecule inhibitors, siRNA or discovery of inhibition of BAP18 transcription to generate miRNA to achieve clinical breast cancer treatment and alleviate the function of breast cancer endocrine therapy resistance. BAP18 only plays a role in promoting cancer progression during the occurrence and development of cancer, and the expression of BAP18 is up-regulated in the vast majority of breast cancer patient tissues. Inhibiting its expression against BAP18 can effectively reduce the side effects caused by other drugs. Combination inhibitor therapy Can effectively increase the clinical treatment effect.
Need to check novelty before this filing date? Find Prior Art

Description

technical field

[0001] The invention belongs to the technical field of biomedicine, and particularly relates to the application of BAP18 in breast cancer endocrine therapy resistance. Background technique

[0002] BAP18 (BPTF associated protein 18KDa) is one of the members of the MLL1 / MOF complex, and it was also found to exist in the NURF complex. interact to perform its function. At present, BAP18 has been reported to be an important androgen receptor (AR) co-regulator, which can upregulate AR-mediated gene transcription and play an important role in prostate cancer and castrated prostate cancer, but other functions of BAP18 are unknown. It has not been reported, especially the function of BAP18 as a chromatin reader needs to be further explored.

[0003] Female breast cancer is one of the most common malignant tumors in women. Clinical diagnostic data show that more than three-quarters of female breast cancers show estrogen receptor positive, and more than 80% of positi...

Examples

Embodiment Construction

[0028] The present invention will be described in further detail below in conjunction with the accompanying drawings and embodiments. The experimental method that does not indicate specific conditions in the embodiment, usually according to conventional conditions, such as the conditions described in textbooks and experimental guides, or according to the conditions suggested by the manufacturer, is well known or easily known to those of ordinary skill in the art, and the following implementations are performed. The examples are only preferred embodiments of the present invention and do not limit the present invention. For those skilled in the art, the present invention may have various modifications and changes. Any modification made within the spirit and principle of the present invention , equivalent replacements, improvements, etc., should all be included within the protection scope of the present invention.

[0029] Example.

[0030] 1. Preparation of inhibitors.

[0031...